# CC-94676-PCA-001 (NCT04428788)

> Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: BMS-986365 plus CC1083611 plus CC1083610
- Indication: metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04428788
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Celgene
- Conditions: Prostatic Neoplasms
- Interventions: CC-94676; CC1083611; CC1083610
- Enrollment: 131
- Primary outcome: Number of participants with adverse events (AEs) evaluated using the NCI CTCAE v5.0 criteria
- Primary outcome: Dose-limiting toxicity (DLT)
- Primary outcome: Non-tolerated dose (NTD)
- Primary outcome: Maximum tolerated dose (MTD)

## Indexed commentary on CC-94676-PCA-001 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=cc-94676-pca-001-nct04428788